Once-Yearly HIV Injection Shows Success in Clinical Trials, Promising End to Daily Medication

The era of daily pills for HIV prevention and treatment is rapidly approaching its twilight. In a major milestone for infectious disease medicine, a once-yearly injection of the antiretroviral medication lenacapavir continues to demonstrate profound success in advanced clinical trials.[1]

For over three decades, the cornerstone of HIV management and pre-exposure prophylaxis (PrEP) has been strict adherence to daily oral regimens. While highly effective, daily pills carry significant burdens: pill fatigue, the stigma of visible medication bottles, and the risk of missed doses leading to viral rebound or new infections.[3]

Building on landmark Phase 1 data published in The Lancet and presented at the Conference on Retroviruses and Opportunistic Infections (CROI), researchers are currently conducting massive Phase 3 trials to evaluate the annual intramuscular injection.[1]

Claim 1: A single injection maintains protective drug levels for a full year. The foundational Phase 1 study enrolled 40 healthy adults without HIV, dividing them into two cohorts to test slightly different formulations of the drug containing varying levels of ethanol.[1]

Following a single 5,000-milligram intramuscular injection, pharmacokinetic monitoring revealed that lenacapavir plasma concentrations increased rapidly and remained above the 95% effective concentration threshold for at least 365 days in both groups.[1]

The evidence here is robust for pharmacokinetics, though it relies on a small initial sample size. At the one-year mark, the median drug concentrations in the blood plasma were actually higher than those observed at the 26-week mark in previous Phase 3 trials of the twice-yearly version of the drug.[3]

Claim 2: The drug's unique mechanism allows for ultra-long-acting formulations. Lenacapavir is a first-in-class HIV capsid inhibitor. Unlike older antiretrovirals that target a single phase of viral replication, lenacapavir interferes with multiple essential steps of the viral lifecycle.[3]

It binds directly to the HIV capsid—the protein shell that protects the virus's genetic material—disrupting both the disassembly of the virus as it enters a healthy cell and the assembly of new viral particles before they can spread.

Because it targets a highly conserved part of the virus, it remains effective even against multidrug-resistant strains. Furthermore, its chemical structure allows it to be formulated as a slow-release depot in the muscle tissue, steadily leaching into the bloodstream over 12 months.[1][3]

Claim 3: The safety profile supports advancing directly to Phase 3. The Phase 1 data showed that the massive 5,000 mg dose was generally well-tolerated. While injection-site reactions such as pain or swelling were common, they were largely mild to moderate and resolved without intervention.[1]

Based on the strength of these pharmacokinetic and safety signals, Gilead Sciences bypassed intermediate Phase 2 efficacy trials entirely. The company is currently running the PURPOSE 365 Phase 3 clinical trial, which launched late last year.[2]

PURPOSE 365 is evaluating the once-yearly injection for PrEP in a large, diverse population of individuals at risk for HIV. If successful, the data could support regulatory filings for approval by late 2027.[2]

Transparent Uncertainty: The risks of an un-withdrawable drug. While the efficacy projections are highly optimistic, the once-yearly format introduces unique clinical challenges. If a patient experiences a severe adverse reaction or develops an allergy to the medication, the drug cannot simply be stopped like a daily pill.[3]

The medication will remain in the patient's system for over a year, requiring medical management of any side effects for the duration of the drug's active life. This makes the ongoing Phase 3 safety monitoring absolutely critical.[2][3]

Furthermore, there is uncertainty regarding the tail phase of the drug. As the concentration slowly drops below the protective threshold at the end of the year, patients who are late for their next annual injection could be exposed to sub-optimal drug levels, theoretically increasing the risk of developing drug-resistant HIV if they acquire the virus during that window.[3]

Claim 4: A once-yearly injection could revolutionize global health equity. Beyond the biochemical achievements, the public health implications of an annual shot are staggering. In low-resource settings, distributing daily pills requires robust, continuous supply chains and frequent clinic visits.

An annual injection could be administered during routine yearly health checkups or massive community health drives, similar to vaccination campaigns. This would bypass the logistical hurdles that currently leave millions without reliable access to PrEP.[3]

However, global health advocates caution that this promise hinges entirely on pricing and patent access. The twice-yearly formulation of lenacapavir faced intense scrutiny over its initial price tag, prompting calls for generic licensing in low- and middle-income countries.

The manufacturer has signaled intentions to allow generic manufacturing for certain high-burden nations, but the exact pricing structure for a once-yearly formulation remains a significant unknown.

Ultimately, the transition from daily pills to a single annual injection represents one of the most significant quality-of-life improvements in the history of HIV medicine. It shifts the paradigm from chronic daily disease management to a model resembling routine preventive care, bringing the world one step closer to ending the HIV epidemic.[3]